澳大利亚多囊卵巢综合征倡导组织(POSAA)和QENDO呼吁将GLP-1减肥药物纳入澳大利亚药物福利计划(PBS)的补贴范围 1。这一诉求针对的是多囊卵巢综合征患者，该慢性激素疾病影响八分之一的女性 1。虽然GLP-1药物在临床中已被医生处方用于治疗该病症，但目前尚未获得官方治疗批准，高昂的月度费用（数百澳元）导致许多患者无法承担这一治疗 1。
根据新南威尔士大学2024年7月的研究，大约五十万澳大利亚人定期使用减肥药物 1。药物福利咨询委员会于去年11月建议将Wegovy用于体重指数超过35的患者 1。制药企业Novo Nordisk表示将继续与卫生部协商PBS列名事宜 1。皇家澳大拉西亚医师学院目前对GLP-1是否适合治疗多囊卵巢综合征没有明确立场 1。
Advocates in Australia are calling for GLP-1 weight loss drugs to be added to the government's Pharmaceutical Benefits Scheme (PBS) to make treatment more affordable for women with polycystic ovary syndrome (PCOS), a chronic hormonal condition affecting one in eight women.1 The Polycystic Ovary Syndrome Australia Association (POSAA) and related organizations argue that while these medications are already prescribed off-label for PCOS in clinical practice, they remain prohibitively expensive—costing hundreds of Australian dollars monthly—preventing many patients from accessing treatment.1
Currently, the medications lack formal approval for treating PCOS, despite evidence supporting their use.1 The Medicines Advisory Committee recommended Wegovy for patients with a body mass index exceeding 35 in November of last year.1 According to a July 2024 study from the University of New South Wales, approximately 500,000 Australians use weight loss medications regularly.1 Novo Nordisk, the manufacturer, has stated it will continue negotiating with the health department regarding PBS listing.1 However, the Royal Australasian College of Physicians has not yet taken a position on whether GLP-1 drugs are appropriate for treating PCOS,1 and medical experts emphasize the need for further research to establish long-term efficacy and safety.1
评论
还没有评论，欢迎留下第一条。